Oportuzumab monatox is a monoclonal antibody drug used to treat advanced ovarian cancer. It works by binding to a protein called mesothelin, which is found in some ovarian cancer cells. This binding triggers the body's immune system to attack the cancer cells, slowing their growth and spread. Oportuzumab monatox is usually used in combination with other treatments, such as chemotherapy and radiation therapy. It is given as an intravenous (IV) infusion every three weeks. Common side effects include fatigue, nausea, anemia, and infusion-related reactions.
Oportuzumab monatox is an investigational drug, meaning it's still under development and not yet widely approved for clinical use [1, 2]. Here's what we know about it so far:
- Target: Oportuzumab monatox is designed to fight cancer. It's a type of anti-cancer medication [2].
- Mechanism: It works as an immunotoxin, which combines two components [1, 2]:
- Monoclonal antibody: Oportuzumab acts as a targeting agent. It's a humanized single-chain fragment that specifically binds to a protein called epithelial cell adhesion molecule (EpCAM), found on the surface of many cancer cells [2].
- Pseudomonas exotoxin A: This is a toxin derived from the bacterium Pseudomonas aeruginosa. Once the antibody binds the cancer cell, the toxin is delivered inside the cell, killing it [1].
- Potential Applications: Research suggests Oportuzumab monatox may be effective in treating various epithelial cancers, which originate in tissues that cover the body's surfaces or line its organs [2]. Some specific cancers studied include:
- Bladder cancer [3]
- Head and neck cancer [5]
Current Status:
- Oportuzumab monatox has undergone clinical trials, showing promising results in some studies, but it has not yet received final approval from regulatory agencies like the US Food and Drug Administration (FDA) [4].
- More research is needed to confirm its efficacy and safety for widespread use.
Important to Remember:
- Since Oportuzumab monatox is investigational, information about its side effects, dosage, and potential interactions with other medications is limited.
- It should only be administered under the supervision of a qualified healthcare professional within a clinical trial setting.